Back to News
Market Impact: 0.2
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
Source: benzinga.com
Market Technicals & Flows
ArriVent BioPharma shares fell Tuesday as trading volume reached 14.10 million shares, versus an average of 524,163. The article does not report the size of the share-price decline or explain its cause.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
AVBP-0.25
More News
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
- US stock market hits all-time high as investors bet big on AI
- Singapore's Temasek warns of the ‘biggest risk’ facing markets right now
- Nvidia Is on the Verge of a $6 Trillion Market Value
- JPMorgan and Deutsche Bank just upgraded Brazilian stocks. How to trade them